Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker

N/AUnknownNCT01198808

Technical University of Munich50 enrolled

Overview

Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and regulatory T cells. The found data will be correlated to clinical data such as the cancer-specific survival and the response to chemotherapy. It is hypothesized that those patients with a high number of Tregs and no tumor-specific T-cells have a worse prognosis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial carcinoma * Age \> 18 years * Hemoglobin \> 10g/dl * Signed Informed Consent * Karnofsky index \< 70% Exclusion Criteria: * Clinically relevant second malignancy * Severe comorbidities (e.g. NYHA III, end-stage renal disease) * Chronic infectious disease (HIV, Tuberculosis) * Immunosupression * Severe psychiatric diseases * Blood donation in the last 4 weeks

Locations (1)

Urologische Klinik der Technischen Universität München

Munich, Bavaria, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.